<p>根据公司在最近向证券交易委员会（SEC）提交的 13F 表格，维吉尼亚退休系统（VIRGINIA RETIREMENT SYSTEMS ET Al）在第三季度增加了对 IDEXX Laboratories, Inc.（NASDAQ:IDXX - 免费报告）股票的持有量，增幅为 29.5%。该基金在此期间购买了额外的 17,500 股后，持有 76,808 股公司的股票。维吉尼亚退休系统在最近一个季度末持有 IDEXX Laboratories 0.10% 的股份，价值 49,072,000 美元。</p>
<ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
<p>其他几家大型投资者也买卖了该公司的股票。Opal Wealth Advisors LLC 在第二季度购买了 IDEXX Laboratories 的新股份，价值 29,000 美元。WealthCollab LLC 在第二季度收购了 IDEXX Laboratories 的新股份，价值 30,000 美元。Armstrong Advisory Group Inc.在第三季度将其在 IDEXX Laboratories 的股份增加了 55.9%。Armstrong Advisory Group Inc.现在持有 53 股公司的股票，价值 34,000 美元，此前在此期间又购买了 19 股。Ameritas Advisory Services LLC 在第二季度购买了 IDEXX Laboratories 的新股份，价值约 36,000 美元。最后，Elevation Point Wealth Partners LLC 在第二季度购买了 IDEXX Laboratories 的新股份，价值约 36,000 美元。目前 87.84% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>IDEXX Laboratories</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师最近对 IDXX 股票发布了报告。Stifel Nicolaus 在 11 月 3 日的研究报告中将 IDEXX Laboratories 的目标价格设定为 775.00 美元。Jefferies Financial Group 在 11 月 4 日的研究报告中重申了 “买入” 评级，并将 IDEXX Laboratories 的目标价格设定为 830.00 美元。巴克莱在 12 月 8 日的研究报告中开始覆盖 IDEXX Laboratories 的股票。他们对该公司给予了 “增持” 评级，并设定了 850.00 美元的目标价格。Weiss Ratings 在 11 月的研究报告中重申了对 IDEXX Laboratories 的 “持有（c+）” 评级。最后，Wall Street Zen 在 11 月 29 日的报告中将 IDEXX Laboratories 的评级从 “强烈买入” 下调至 “买入”。七位分析师对该股票给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat 的数据，IDEXX Laboratories 目前的平均评级为 “适度买入”，平均目标价格为 763.50 美元。</p>
<p><strong>获取我们最新的 IDEXX Laboratories 股票报告</strong></p>
<h2>IDEXX Laboratories 股票表现</h2>
<p>IDXX 的股票在周三开盘价为 682.32 美元。该公司的市值为 544.8 亿美元，市盈率为 54.11，PEG 比率为 4.10，贝塔值为 1.67。IDEXX Laboratories, Inc.的 12 个月最低价为 356.14 美元，最高价为 769.98 美元。该公司的债务与股本比率为 0.24，速动比率为 0.87，流动比率为 1.18。该公司的 50 日移动平均价格为 697.50 美元，200 日移动平均价格为 635.11 美元。</p>
<p>IDEXX Laboratories（NASDAQ:IDXX - 获取免费报告）最近在 11 月 3 日发布了季度财报。该公司报告的季度每股收益为 3.22 美元，超出分析师一致预期的 3.14 美元，超出幅度为 0.08 美元。该公司的季度收入为 11.1 亿美元，而分析师预期为 10.7 亿美元。IDEXX Laboratories 的净利润率为 24.65%，股本回报率为 67.78%。该公司的季度收入同比增长了 13.3%。去年同期，该公司的每股收益为 2.80 美元。IDEXX Laboratories 已将其 2025 财年的指导目标设定为 12.810-13.010 每股收益。分析师平均预测 IDEXX Laboratories, Inc.在当前财年将发布 11.93 每股收益。</p>
<h2>内部活动</h2>
<p>在其他新闻中，执行副总裁 Nimrata Hunt 在 11 月 7 日的交易中出售了 9,425 股公司的股票。该股票以 703.34 美元的平均价格出售，总价值为 6,628,979.50 美元。出售后，该执行副总裁直接持有公司 21,149 股，价值 14,874,937.66 美元。此次交易使其持股减少了 30.83%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。0.98% 的股票由公司内部人士持有。</p>
<h2>关于 IDEXX Laboratories</h2>
<p>（免费报告）</p>
<p>IDEXX Laboratories, Inc NASDAQ: IDXX 是一家全球开发、制造和提供诊断产品和服务的公司，主要面向动物健康、水质检测和食品安全市场。公司总部位于缅因州韦斯特布鲁克，提供临床诊断仪器、耗材、参考实验室测试和实践管理工具，支持全球的兽医、畜牧和乳制品生产商以及公用事业和食品生产商。</p>
<p>IDEXX 的产品组合包括用于兽医诊所快速诊断的即时检测和免疫测定、临床化学和血液学分析仪、自动化尿液分析系统以及数字诊断解决方案。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 IDEXX Laboratories</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微小的 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUlEWFg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUlEWFg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
<p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 IDEXX Laboratories 并不在名单上。</p>
<p>虽然 IDEXX Laboratories 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IDEXX实验室

<p>维吉尼亚退休系统等在第三季度将其在 IDEXX 实验室的股份增加了 29.5%，目前持有 76,808 股，价值 4907 万美元。其他投资者也增持了该公司的股份。分析师设定的目标价格范围为 775 美元至 850 美元，普遍评级为 “适度买入”。IDEXX 报告的季度每股收益为 3.22 美元，超出预期，收入为 11.1 亿美元，同比增长 13.3%。内部人士活动包括执行副总裁 Nimrata Hunt 出售了 9,425 股</p>

<p>VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 29.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,808 shares of the company's stock after buying an additional 17,500 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.10% of IDEXX Laboratories worth $49,072,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会（SEC）提交的 13F 表格，维吉尼亚退休系统（VIRGINIA RETIREMENT SYSTEMS ET Al）在第三季度增加了对 IDEXX Laboratories, Inc.（NASDAQ:IDXX - 免费报告）股票的持有量，增幅为 29.5%。该基金在此期间购买了额外的 17,500 股后，持有 76,808 股公司的股票。维吉尼亚退休系统在最近一个季度末持有 IDEXX Laboratories 0.10% 的股份，价值 49,072,000 美元。</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
</div><p>Several other large investors have also bought and sold shares of the business. Opal Wealth Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $30,000. Armstrong Advisory Group Inc. grew its stake in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock worth $34,000 after purchasing an additional 19 shares during the period. Ameritas Advisory Services LLC bought a new stake in IDEXX Laboratories in the second quarter valued at about $36,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in IDEXX Laboratories in the second quarter valued at about $36,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家大型投资者也买卖了该公司的股票。Opal Wealth Advisors LLC 在第二季度购买了 IDEXX Laboratories 的新股份，价值 29,000 美元。WealthCollab LLC 在第二季度收购了 IDEXX Laboratories 的新股份，价值 30,000 美元。Armstrong Advisory Group Inc.在第三季度将其在 IDEXX Laboratories 的股份增加了 55.9%。Armstrong Advisory Group Inc.现在持有 53 股公司的股票，价值 34,000 美元，此前在此期间又购买了 19 股。Ameritas Advisory Services LLC 在第二季度购买了 IDEXX Laboratories 的新股份，价值约 36,000 美元。最后，Elevation Point Wealth Partners LLC 在第二季度购买了 IDEXX Laboratories 的新股份，价值约 36,000 美元。目前 87.84% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>IDEXX Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>IDEXX Laboratories</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts have recently issued reports on IDXX shares. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Jefferies Financial Group reissued a &#34;buy&#34; rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Barclays began coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They issued an &#34;overweight&#34; rating and a $850.00 target price for the company. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of IDEXX Laboratories in a research report on Monday. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 29th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $763.50.</p>
<div class="lb-trans"><p>几位股票分析师最近对 IDXX 股票发布了报告。Stifel Nicolaus 在 11 月 3 日的研究报告中将 IDEXX Laboratories 的目标价格设定为 775.00 美元。Jefferies Financial Group 在 11 月 4 日的研究报告中重申了 “买入” 评级，并将 IDEXX Laboratories 的目标价格设定为 830.00 美元。巴克莱在 12 月 8 日的研究报告中开始覆盖 IDEXX Laboratories 的股票。他们对该公司给予了 “增持” 评级，并设定了 850.00 美元的目标价格。Weiss Ratings 在 11 月的研究报告中重申了对 IDEXX Laboratories 的 “持有（c+）” 评级。最后，Wall Street Zen 在 11 月 29 日的报告中将 IDEXX Laboratories 的评级从 “强烈买入” 下调至 “买入”。七位分析师对该股票给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat 的数据，IDEXX Laboratories 目前的平均评级为 “适度买入”，平均目标价格为 763.50 美元。</p>
</div><p><strong>Get Our Latest Stock Report on IDEXX Laboratories</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 IDEXX Laboratories 股票报告</strong></p>
</div><h2>IDEXX Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 股票表现</h2>
</div><p>Shares of IDXX opened at $682.32 on Wednesday. The firm has a market cap of $54.48 billion, a P/E ratio of 54.11, a PEG ratio of 4.10 and a beta of 1.67. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. The firm's 50 day moving average price is $697.50 and its two-hundred day moving average price is $635.11.</p>
<div class="lb-trans"><p>IDXX 的股票在周三开盘价为 682.32 美元。该公司的市值为 544.8 亿美元，市盈率为 54.11，PEG 比率为 4.10，贝塔值为 1.67。IDEXX Laboratories, Inc.的 12 个月最低价为 356.14 美元，最高价为 769.98 美元。该公司的债务与股本比率为 0.24，速动比率为 0.87，流动比率为 1.18。该公司的 50 日移动平均价格为 697.50 美元，200 日移动平均价格为 635.11 美元。</p>
</div><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts' consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm's quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the business posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>IDEXX Laboratories（NASDAQ:IDXX - 获取免费报告）最近在 11 月 3 日发布了季度财报。该公司报告的季度每股收益为 3.22 美元，超出分析师一致预期的 3.14 美元，超出幅度为 0.08 美元。该公司的季度收入为 11.1 亿美元，而分析师预期为 10.7 亿美元。IDEXX Laboratories 的净利润率为 24.65%，股本回报率为 67.78%。该公司的季度收入同比增长了 13.3%。去年同期，该公司的每股收益为 2.80 美元。IDEXX Laboratories 已将其 2025 财年的指导目标设定为 12.810-13.010 每股收益。分析师平均预测 IDEXX Laboratories, Inc.在当前财年将发布 11.93 每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Nimrata Hunt sold 9,425 shares of the business's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.98% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Nimrata Hunt 在 11 月 7 日的交易中出售了 9,425 股公司的股票。该股票以 703.34 美元的平均价格出售，总价值为 6,628,979.50 美元。出售后，该执行副总裁直接持有公司 21,149 股，价值 14,874,937.66 美元。此次交易使其持股减少了 30.83%。该出售在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。0.98% 的股票由公司内部人士持有。</p>
</div><h2>About IDEXX Laboratories</h2>
<div class="lb-trans"><h2>关于 IDEXX Laboratories</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.</p>
<div class="lb-trans"><p>IDEXX Laboratories, Inc NASDAQ: IDXX 是一家全球开发、制造和提供诊断产品和服务的公司，主要面向动物健康、水质检测和食品安全市场。公司总部位于缅因州韦斯特布鲁克，提供临床诊断仪器、耗材、参考实验室测试和实践管理工具，支持全球的兽医、畜牧和乳制品生产商以及公用事业和食品生产商。</p>
</div><p>IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.</p>
<div class="lb-trans"><p>IDEXX 的产品组合包括用于兽医诊所快速诊断的即时检测和免疫测定、临床化学和血液学分析仪、自动化尿液分析系统以及数字诊断解决方案。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than IDEXX Laboratories</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 IDEXX Laboratories</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微小的 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IDXX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
</div><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 IDEXX Laboratories 并不在名单上。</p>
</div><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IDEXX Laboratories 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

弗吉尼亚退休系统等持有 IDEXX 实验室公司价值 4907 万美元的股份